Last reviewed · How we verify
Meropenem Infusion
Meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Serious bacterial infections including intra-abdominal infections, Bacterial meningitis, Lower respiratory tract infections.
At a glance
| Generic name | Meropenem Infusion |
|---|---|
| Also known as | Meropenem or Merrem(R) |
| Sponsor | Unity Health Toronto |
| Drug class | Carbapenem antibiotic |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Meropenem is a carbapenem antibiotic that penetrates bacterial cell walls and binds to penicillin-binding proteins, inhibiting cross-linking of peptidoglycan and leading to cell wall degradation and bacterial death. It has activity against a wide range of gram-positive and gram-negative bacteria, including anaerobes, making it effective for serious infections caused by susceptible organisms.
Approved indications
- Complicated intra-abdominal infections
- Bacterial meningitis
- Complicated skin and soft tissue infections
- Febrile neutropenia
- Nosocomial pneumonia
- Urinary tract infections
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Headache
- Phlebitis at injection site
- Rash
- Seizures
Key clinical trials
- A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
- A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP (PHASE3)
- Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex (PHASE3)
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis (PHASE2)
- Clearance of Antibacterial Agents During Hemoperfusion in Patients With Sepsis
- Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections (PHASE3)
- Comparison Between Carbapenems and Noncarbapenem Beta-lactam Antibiotics in Septic Burn Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meropenem Infusion CI brief — competitive landscape report
- Meropenem Infusion updates RSS · CI watch RSS
- Unity Health Toronto portfolio CI